Related Experiment Video

Updated: Apr 7, 2026

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

954

Expression of the receptor for advanced glycation end-products and frequency of polymorphism in lung cancer

Hongmei Wang1, Yongchun Li2, Wencheng Yu3

  • 1Department of Respiratory Medicine, The Affiliated Hospital of Qingdao University, Qingdao, Shandong 266003, P.R. China ; Department of Respiratory Medicine, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.

Oncology Letters
|July 15, 2015
PubMed

Insights

Levels of soluble Receptor for Advanced Glycation End Products (sRAGE) are lower in lung cancer patients. RAGE gene polymorphisms are linked to lung cancer development and progression, suggesting potential diagnostic biomarkers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Receptor for Advanced Glycation End Products (RAGE) signaling is implicated in cancer progression.
  • Soluble RAGE (sRAGE) acts as a physiological inhibitor of RAGE-mediated pathological effects.

Purpose of the Study:

  • To investigate the expression of sRAGE, RAGE, and RAGE ligands in lung cancer patients.
  • To analyze RAGE gene polymorphisms in relation to lung cancer genesis and progression.
  • To explore RAGE's role in lung cancer diagnosis and prognosis.

Main Methods:

  • Enzyme-linked immunosorbent assay (ELISA) for serum analysis.
  • Immunohistochemistry for tissue expression analysis.
  • Genotyping for RAGE polymorphisms (-429T/C and 2184A/G).

Main Results:

  • sRAGE levels were downregulated in serum samples.
  • RAGE expression was decreased in lung cancer tissues.
  • RAGE ligands HMGB1 and S100 were upregulated in cancer tissues.
  • Specific RAGE polymorphisms (-429T/C and 2184A/G) were associated with lung cancer development and progression.

Conclusions:

  • Aberrant expression of sRAGE, RAGE, and its ligands is observed in lung cancer.
  • RAGE gene polymorphisms may contribute to lung cancer pathogenesis.
  • RAGE pathway components and polymorphisms show potential as diagnostic and prognostic biomarkers for lung cancer.
Keywords:
RAGERAGE polymorphismlung cancersoluble RAGE

More Related Videos

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay10:57

Visualizing Genetic Variants, Short Targets, and Point Mutations in the Morphological Tissue Context with an RNA In Situ Hybridization Assay

Published on: August 14, 2018

11.3K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.5K
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
116
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K